Verunreinigungen der Aminosäure, die zur Syntheseprotein verwendet wird
Produktdetail
| NO | Produkte | Cas Nr | Schlüsselqualitätsindikator | |||
| Reinheit | Max. Verunreinigung | Gesamtlösungsmittelreste | Feuchtigkeit | |||
| 1 | FMOC-β-ala-ala-oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 2 | FMOC-D-ALA-D-ALA-OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 3 | FMOC-β-ala-d-ala-oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 4 | FMOC-ARG (PBF) -ARG (PBF) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 5 | FMOC-β-ala-Arg (PBF) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 6 | FMOC-D-ARG (PBF) -D-ARG (PBF) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 7 | FMOC-β-ALA-D-ARG (PBF) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 8 | Fmoc-homoarg (pbf) -homoarg (pbf) -Oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 9 | FMOC-β-ala-Homoarg (PBF) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 10 | FMOC-ASN (TRT)-ASN (TRT) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 11 | FMOC-β-ALA-ASN (TRT) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 12 | FMOC-ASP (OTBU) -asp (OTBU) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 13 | FMOC-β-ala-ASP (OTBU) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 14 | FMOC-Cys (TRT) -Cys (TRT) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 15 | FMOC-β-ALA-Cys (TRT) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 16 | FMOC-Cys (ACM) -Cys (ACM) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 17 | FMOC-β-ALA-Cys (ACM) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 18 | FMOC-GLN (TRT) -GLN (TRT) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 19 | FMOC-β-ALA-GLN (TRT) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 20 | Fmoc-glu (otbu) -glu (OTBU) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 21 | FMOC-β-ALA-Glu (OTBU) -OH.H2O | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 22 | FMOC-β-ala-Gly-oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 23 | Fmoc-his (trt) -his (trt) -Oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 24 | FMOC-β-Ala-HIS (TRT) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 25 | Fmoc-ile-iil-oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 26 | FMOC-β-ala-iil-oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 27 | Fmoc-leu-leu-oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 28 | FMOC-β-ala-leu-oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 29 | FMOC-D-Leu-D-Leu-oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 30 | FMOC-β-ala-d-leu-oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 31 | Fmoc-lys (boc) -lys (boc) -Oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 32 | FMOC-β-Ala-Lys (BOC) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 33 | FMoc-lys (alloc) -lys (alloc) -Oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 34 | FMOC-β-Ala-Lys (Alloc) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 35 | Fmoc-met-met-oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 36 | FMOC-β-ala-met-oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 37 | FMOC-ARN (BOC) -ORN (BOC) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 38 | FMOC-β-ALA-ARN (BOC) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 39 | FMOC-PHE-PHE-OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 40 | FMOC-β-Ala-PHE-OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 41 | FMOC-D-PHE-D-PHE-OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 42 | FMOC-β-ALA-D-PHE-OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 43 | Fmoc-pro-pro-oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 44 | FMOC-β-ala-pro-oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 45 | FMOC-SER (TBU) -ser (TBU) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 46 | FMOC-β-ala-Ser (TBU) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 47 | FMOC-Ser (TRT) -ser (TRT) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 48 | FMOC-β-ala-Ser (TRT) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 49 | FMOC-Thr (TBU) -Thr (TBU) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 50 | FMOC-β-ALA-THR (TBU) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 51 | FMOC-TRP (BOC) -TRP (BOC) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 52 | FMOC-β-ALA-TRP (BOC) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 53 | FMOC-D-TRP (BOC) -D-TRP (BOC) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 54 | FMOC-β-ALA-D-TRP (BOC) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 55 | FMOC-TYR (TBU) -TYR (TBU) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 56 | FMOC-β-ala-Tyr (TBU) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 57 | FMOC-D-TYR (ET) -D-TYR (ET) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 58 | FMOC-β-ALA-D-TYR (ET) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 59 | Fmoc-tyr (me) -tyr (me) -Oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 60 | FMOC-β-ala-Tyr (ME) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 61 | FMOC-VAL-VAL-OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 62 | FMOC-β-ala-val-oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 63 | Fmoc-d-cit-d-cit-oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 64 | FMOC-β-ALA-D-CIT-OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 65 | FMOC-β-ala-DAB-OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 66 | FMoc- (3- (2-naphthyl) -d-ala) 2-oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 67 | FMOC-β-ala-3- (2-Naphthyl) -d-ala-oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 68 | FMOC- (3- (3-Pyridinyl) -D-ala) 2-oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 69 | FMOC-β-ala-3- (3-Pyridinyl) -d-ala-oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 70 | FMOC- (4-Chloro-d-Phe) 2-OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 71 | FMOC-β-ala-4-Chloro-d-Phe-oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 72 | FMOC- (D-4APH (TBUCBM)) 2-OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 73 | FMOC-β-ALA-D-4APH (TBUCBM) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 74 | FMOC-APH (L-HOR) -APH (L-HOR) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 75 | FMOC-β-Ala-APH (L-HOR) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 76 | FMOC-Lys (IPR, BOC) -lys (IPR, BOC) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 77 | FMOC-β-Ala-Lys (IPR, BOC) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 78 | FMOC-β-ala-aaea-oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 79 | FMOC-AIB-AIB-OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 80 | FMOC-β-Ala-AIB-OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 81 | Fmoc-arg-oh | 91000-69-0 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 82 | H-Arg (PBF) -OH | 200115-86-2 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 83 | FMOC-D-ARG-OH | 130752-32-8 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 84 | HD-Arg (PBF) -OH | 200116-81-0 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 85 | Fmoc-homoarg-oh.hcl | 208174-14-5 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 86 | H-Homoarg (PBF) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 87 | Fmoc-d-homoarg-oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 88 | HD-Homoarg (PBF) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 89 | FMOC-asn-oh | 71989-16-7 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 90 | H-asn (trt) -Oh | 132388-58-0 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 91 | Fmoc-asp-oh | 119062-05-4 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 92 | H-asp (OTBU) -OH | 3057-74-7 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 93 | Fmoc-cys-oh | 135248-89-4 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 94 | H-Cys (TRT) -OH | 2799/7/7 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 95 | H-Cys (ACM) -Oh.hcl | 28798-28-9 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 96 | Fmoc-gln-oh | 71989-20-3 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 97 | H-gln (trt) -Oh | 102747-84-2 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 98 | Fmoc-glu-oh | 121343-82-6 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 99 | H-Glu (OTBU) -OH.H2O | 2419-56-9 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 100 | Fmoc-his-oh | 116611-64-4 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 101 | H-His (Trt) -Oh | 35146-32-8 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 102 | Boc-his-oh | 17791-52-5 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 103 | Fmoc-lys-oh | 105047-45-8 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 104 | H-Lys (BOC) -OH | 2418-95-3 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 105 | H-Lys (Alloc) -Oh | 6298/3/9 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 106 | Fmoc-orn-oh.hcl | 201046-57-3 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 107 | H-erorn (boc) -Oh | 13650-49-2 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 108 | Fmoc-ser-oh | 73724-45-5 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 109 | H-Ser (TBU) -OH | 18822-58-7 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 110 | H-ser (trt) -Oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 111 | Fmoc-thr-oh.h2o | 73731-37-0 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 112 | H-Thr (tbu) -Oh | 4378-13-6 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 113 | Fmoc-trp-oh | 35737-15-6 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 114 | H-trp (boc) -Oh | 146645-63-8 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 115 | Fmoc-d-trp-oh | 86123-11-7 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 116 | HD-TRP (BOC) -OH | 201290-11-1 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 117 | FMOC-TYR-OH | 92954-90-0 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 118 | H-Tyr (TBU) -OH | 18822-59-8 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 119 | FMOC-D-TYR-OH | 112883-29-1 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 120 | HD-Tyr (et) -Oh | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 121 | H-Tyr (ich) -Oh.hcl | 67423-44-3 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 122 | FMOC-D-4APH (CBM) -OH | 324017-22-3 | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 123 | HD-4APH (TBUCBM) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 124 | FMOC-Lys (IPR) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
| 125 | H-Lys (IPR, BOC) -OH | NA | ≥ 98,0% | ≤ 1,0% | ≤ 8,0% | ≤ 2,0% |
Um
Entschädigung
Gentolex liefert hervorragende Produkte, wenn die Produktqualität vom Kunden innerhalb des erforderlichen Zeitrahmens mit ausreichenden Nachweisen angehoben wird, werden wir die erforderliche Analyse und Bewertung vorlegen, um die Verfahren von Kompensationen auszulösen.
Produktion
Die Kapazitäten der pharmazeutischen Produkte erreichten die Tonnennote, die Kapazitäten der chemischen Produkte erreichen 100 Tonnen+ Grad, die Fähigkeiten sind gut ausgestattet, um Kunden weltweit zu bedienen.
Forschung und Entwicklung
Jedes Jahr wird vom F & E -Team ein Plan erstellt, um verschiedene neue Produkte zu entwickeln. Wenn Ziele festgelegt werden, muss jedes Mitglied des Teams die KPI -Verantwortung und die Incentive -Richtlinie fortsetzen.
